Human Infection with Ascaris lumbricoides Is Associated with Suppression of the Interleukin-2 Response to Recombinant Cholera Toxin B Subunit following Vaccination with the Live Oral Cholera Vaccine CVD 103-HgR
Classifications Services IAI Citing Articles Google Scholar PubMed Related Content Social Bookmarking CiteULike Delicious Digg Facebook Google+ Mendeley Reddit StumbleUpon Twitter current issue Spotlights in the Current Issue IAI About IAI Subscribers Authors Reviewers Advertisers Inquiries from the...
Saved in:
| Published in | Infection and Immunity Vol. 69; no. 3; pp. 1574 - 1580 |
|---|---|
| Main Authors | , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
Washington, DC
American Society for Microbiology
01.03.2001
|
| Subjects | |
| Online Access | Get full text |
Cover
Loading…
| Abstract | Classifications
Services
IAI
Citing Articles
Google Scholar
PubMed
Related Content
Social Bookmarking
CiteULike
Delicious
Digg
Facebook
Google+
Mendeley
Reddit
StumbleUpon
Twitter
current issue
Spotlights in the Current Issue
IAI
About
IAI
Subscribers
Authors
Reviewers
Advertisers
Inquiries from the Press
Permissions & Commercial Reprints
ASM Journals Public Access Policy
Connect to IAI
IAI
RSS Feeds
1752 N Street N.W. • Washington DC 20036
202.737.3600 • 202.942.9355 fax • journals@asmusa.org
Print ISSN:
0019-9567
Online ISSN:
1098-5522
Copyright © 2014
by the
American Society for Microbiology.
For an alternate route to
IAI
.asm.org, visit:
IAI
|
|---|---|
| AbstractList | To investigate the potential immunomodulatory effects of concurrent ascariasis on the cytokine response to a live oral vaccine, we measured cytokine responses to cholera toxin B subunit (CT-B) following vaccination with the live oral cholera vaccine CVD 103-HgR in
Ascaris lumbricoides
-infected subjects randomized in a double-blind study to receive two doses of either albendazole or placebo prior to vaccination and in a group of healthy U.S. controls. Postvaccination cytokine responses to CT-B were characterized by transient increases in the production of interleukin-2 (IL-2;
P
= 0.02) and gamma interferon (IFN-γ;
P
= 0.001) in the three study groups combined; however, postvaccination increases in IFN-γ were significant only in the albendazole-treated
A. lumbricoides
infection group (
P
= 0.008). Postvaccination levels of IL-2 were significantly greater in the albendazole-treated group compared with the placebo group (
P
= 0.03). No changes in levels of Th1 and Th2 cytokines in response to control ascaris antigens were observed over the same period. These findings indicate that vaccination with CVD 103-HgR is associated with a Th1 cytokine response (IL-2 and IFN-γ) to CT-B, that infection with
A. lumbricoides
diminishes the magnitude of this response, and that albendazole treatment prior to vaccination was able to partially reverse the deficit in IL-2. The potential modulation of the immune response to oral vaccines by geohelminth parasites has important implications for the design of vaccination campaigns in geohelminth-endemic areas. To investigate the potential immunomodulatory effects of concurrent ascariasis on the cytokine response to a live oral vaccine, we measured cytokine responses to cholera toxin B subunit (CT-B) following vaccination with the live oral cholera vaccine CVD 103-HgR in Ascaris lumbricoides-infected subjects randomized in a double-blind study to receive two doses of either albendazole or placebo prior to vaccination and in a group of healthy U.S. controls. Postvaccination cytokine responses to CT-B were characterized by transient increases in the production of interleukin-2 (IL-2; P = 0.02) and gamma interferon (IFN-gamma; P = 0.001) in the three study groups combined; however, postvaccination increases in IFN-gamma were significant only in the albendazole-treated A. lumbricoides infection group (P = 0.008). Postvaccination levels of IL-2 were significantly greater in the albendazole-treated group compared with the placebo group (P = 0.03). No changes in levels of Th1 and Th2 cytokines in response to control ascaris antigens were observed over the same period. These findings indicate that vaccination with CVD 103-HgR is associated with a Th1 cytokine response (IL-2 and IFN-gamma) to CT-B, that infection with A. lumbricoides diminishes the magnitude of this response, and that albendazole treatment prior to vaccination was able to partially reverse the deficit in IL-2. The potential modulation of the immune response to oral vaccines by geohelminth parasites has important implications for the design of vaccination campaigns in geohelminth-endemic areas.To investigate the potential immunomodulatory effects of concurrent ascariasis on the cytokine response to a live oral vaccine, we measured cytokine responses to cholera toxin B subunit (CT-B) following vaccination with the live oral cholera vaccine CVD 103-HgR in Ascaris lumbricoides-infected subjects randomized in a double-blind study to receive two doses of either albendazole or placebo prior to vaccination and in a group of healthy U.S. controls. Postvaccination cytokine responses to CT-B were characterized by transient increases in the production of interleukin-2 (IL-2; P = 0.02) and gamma interferon (IFN-gamma; P = 0.001) in the three study groups combined; however, postvaccination increases in IFN-gamma were significant only in the albendazole-treated A. lumbricoides infection group (P = 0.008). Postvaccination levels of IL-2 were significantly greater in the albendazole-treated group compared with the placebo group (P = 0.03). No changes in levels of Th1 and Th2 cytokines in response to control ascaris antigens were observed over the same period. These findings indicate that vaccination with CVD 103-HgR is associated with a Th1 cytokine response (IL-2 and IFN-gamma) to CT-B, that infection with A. lumbricoides diminishes the magnitude of this response, and that albendazole treatment prior to vaccination was able to partially reverse the deficit in IL-2. The potential modulation of the immune response to oral vaccines by geohelminth parasites has important implications for the design of vaccination campaigns in geohelminth-endemic areas. Classifications Services IAI Citing Articles Google Scholar PubMed Related Content Social Bookmarking CiteULike Delicious Digg Facebook Google+ Mendeley Reddit StumbleUpon Twitter current issue Spotlights in the Current Issue IAI About IAI Subscribers Authors Reviewers Advertisers Inquiries from the Press Permissions & Commercial Reprints ASM Journals Public Access Policy Connect to IAI IAI RSS Feeds 1752 N Street N.W. • Washington DC 20036 202.737.3600 • 202.942.9355 fax • journals@asmusa.org Print ISSN: 0019-9567 Online ISSN: 1098-5522 Copyright © 2014 by the American Society for Microbiology. For an alternate route to IAI .asm.org, visit: IAI To investigate the potential immunomodulatory effects of concurrent ascariasis on the cytokine response to a live oral vaccine, we measured cytokine responses to cholera toxin B subunit (CT-B) following vaccination with the live oral cholera vaccine CVD 103-HgR in Ascaris lumbricoides-infected subjects randomized in a double-blind study to receive two doses of either albendazole or placebo prior to vaccination and in a group of healthy U.S. controls. Postvaccination cytokine responses to CT-B were characterized by transient increases in the production of interleukin-2 (IL-2; P = 0.02) and gamma interferon (IFN- gamma ; P = 0.001) in the three study groups combined; however, postvaccination increases in IFN- gamma were significant only in the albendazole-treated A. lumbricoides infection group (P = 0.008). Postvaccination levels of IL-2 were significantly greater in the albendazole-treated group compared with the placebo group (P = 0.03). No changes in levels of Th1 and Th2 cytokines in response to control ascaris antigens were observed over the same period. These findings indicate that vaccination with CVD 103-HgR is associated with a Th1 cytokine response (IL-2 and IFN- gamma ) to CT-B, that infection with A. lumbricoides diminishes the magnitude of this response, and that albendazole treatment prior to vaccination was able to partially reverse the deficit in IL-2. The potential modulation of the immune response to oral vaccines by geohelminth parasites has important implications for the design of vaccination campaigns in geohelminth-endemic areas. |
| Author | Martha Chico Angel Guevara Ivan Espinel Philip J. Cooper Carlos Sandoval Thomas B. Nutman George E. Griffin Myron M. Levine |
| AuthorAffiliation | Laboratory of Parasitic Diseases, National Institutes of Health, Bethesda, Maryland 20892 1 ; Department of Clinical Investigations, Hospital Vozandes, Quito, Ecuador 2 ; Center for Vaccine Development, University of Maryland, Baltimore, Maryland 21201 3 ; and St. George's Hospital Medical School, Tooting, London, United Kingdom 4 |
| AuthorAffiliation_xml | – name: Laboratory of Parasitic Diseases, National Institutes of Health, Bethesda, Maryland 20892 1 ; Department of Clinical Investigations, Hospital Vozandes, Quito, Ecuador 2 ; Center for Vaccine Development, University of Maryland, Baltimore, Maryland 21201 3 ; and St. George's Hospital Medical School, Tooting, London, United Kingdom 4 |
| Author_xml | – sequence: 1 givenname: Philip J. surname: Cooper fullname: Cooper, Philip J. organization: <!--label omitted: 1-->Laboratory of Parasitic Diseases, National Institutes of Health, Bethesda, Maryland 208921 – sequence: 2 givenname: Martha surname: Chico fullname: Chico, Martha organization: <!--label omitted: 2-->Department of Clinical Investigations, Hospital Vozandes, Quito, Ecuador2 – sequence: 3 givenname: Carlos surname: Sandoval fullname: Sandoval, Carlos organization: <!--label omitted: 2-->Department of Clinical Investigations, Hospital Vozandes, Quito, Ecuador2 – sequence: 4 givenname: Ivan surname: Espinel fullname: Espinel, Ivan organization: <!--label omitted: 2-->Department of Clinical Investigations, Hospital Vozandes, Quito, Ecuador2 – sequence: 5 givenname: Angel surname: Guevara fullname: Guevara, Angel organization: <!--label omitted: 2-->Department of Clinical Investigations, Hospital Vozandes, Quito, Ecuador2 – sequence: 6 givenname: Myron M. surname: Levine fullname: Levine, Myron M. organization: <!--label omitted: 3-->Center for Vaccine Development, University of Maryland, Baltimore, Maryland 212013; and – sequence: 7 givenname: George E. surname: Griffin fullname: Griffin, George E. organization: <!--label omitted: 4-->St. George's Hospital Medical School, Tooting, London, United Kingdom4 – sequence: 8 givenname: Thomas B. surname: Nutman fullname: Nutman, Thomas B. organization: <!--label omitted: 1-->Laboratory of Parasitic Diseases, National Institutes of Health, Bethesda, Maryland 208921 |
| BackLink | http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=14162131$$DView record in Pascal Francis https://www.ncbi.nlm.nih.gov/pubmed/11179329$$D View this record in MEDLINE/PubMed |
| BookMark | eNqNks2O0zAUhSM0iOkMvAKYBexS7MSJHQkWpfy0UqWRhmG2luPctIbELrYzhdfkiXBoaYENrGxff-fo6t5zkZwZayBJnhA8JSTjL5az5bSspvmUFIympOB4mmFM7iUTgiueFkWWnSWTWKnSqijZeXLh_af4pJTyB8k5IYRVeVZNku-LoZcGLU0LKmhr0E6HDZp5JZ32qBv62mlldQMeLX2se6u0DNDsuQ_DduvA-1FoWxQ2EJ0CuA6Gz9qkGboGv7XGAwo23pXta22kCWi-sR04iW7sV23Q62hUD0YH1Nqusztt1uhWKhXZU0-j-UrfAbpysjsa7DFA89s3iOA8XayvHyb3W9l5eHQ4L5OP797ezBfp6ur9cj5bpYoyHlKgmLOiJVVGGc6aslG0KYG3tMy5hJzUnKiK5ZhKDBlripJTqlhbNwwUNHWTXyYv977boe6hUWBC7Exsne6l-yas1OLPH6M3Ym3vRMVxwaP8-UHu7JcBfBC99gq6ThqwgxcMl1mVl-yfIGG8JARnEXz8e0PHTn5tOwLPDoCMC-5aJ43S_sRRUmYkJ5Fje045672D9oRgMeZPxPyJshK5GPMnxvyJMX9R-eovpdLh5xLjBHT3H_qne_1Grzc77UBI3wsdR3mk8x8n7_Ap |
| CODEN | INFIBR |
| CitedBy_id | crossref_primary_10_1016_S1473_3099_06_70630_2 crossref_primary_10_1371_journal_pone_0009309 crossref_primary_10_1016_S0001_706X_03_00063_9 crossref_primary_10_1111_j_1440_1711_2005_01404_x crossref_primary_10_1086_591945 crossref_primary_10_1093_infdis_jix585 crossref_primary_10_1002_pmic_200600068 crossref_primary_10_1093_intimm_dxh375 crossref_primary_10_1371_journal_pntd_0012520 crossref_primary_10_1080_15321819_2024_2426147 crossref_primary_10_1371_journal_pone_0292408 crossref_primary_10_1111_j_1365_3024_2006_00909_x crossref_primary_10_1371_journal_pntd_0003537 crossref_primary_10_1016_j_exppara_2011_06_001 crossref_primary_10_1098_rstb_2014_0144 crossref_primary_10_1016_j_cyto_2004_07_004 crossref_primary_10_1371_journal_pntd_0007455 crossref_primary_10_1016_j_etap_2017_07_016 crossref_primary_10_1371_journal_pone_0019197 crossref_primary_10_1007_s10620_007_9927_9 crossref_primary_10_1128_msphere_00478_24 crossref_primary_10_1038_mi_2009_23 crossref_primary_10_1016_j_parepi_2016_12_003 crossref_primary_10_1128_CMR_00012_07 crossref_primary_10_1002_eji_201141955 crossref_primary_10_1101_cshperspect_a029256 crossref_primary_10_1172_JCI121053 crossref_primary_10_1016_j_imlet_2023_03_001 crossref_primary_10_1155_2012_132583 crossref_primary_10_1016_S1473_3099_11_70341_3 crossref_primary_10_1371_journal_pntd_0003768 crossref_primary_10_1186_s13071_019_3471_2 crossref_primary_10_1371_journal_pone_0041205 crossref_primary_10_1128_IAI_70_11_6058_6067_2002 crossref_primary_10_1111_pim_12442 crossref_primary_10_1016_j_vaccine_2020_06_064 crossref_primary_10_1128_AEM_72_3_2178_2184_2006 crossref_primary_10_1016_j_ijpara_2014_03_012 crossref_primary_10_1128_IAI_74_4_2138_2144_2006 crossref_primary_10_1186_1741_7007_8_129 crossref_primary_10_1111_pim_12525 crossref_primary_10_1016_j_pt_2008_02_009 crossref_primary_10_1046_j_1444_1586_2001_00002_x crossref_primary_10_1111_j_1348_0421_2006_tb03866_x crossref_primary_10_1021_es050659a crossref_primary_10_4049_jimmunol_1003778 crossref_primary_10_1093_infdis_jiw156 crossref_primary_10_1038_nrmicro962 crossref_primary_10_1186_s13071_015_1167_9 crossref_primary_10_1016_j_ijpara_2016_08_007 crossref_primary_10_3389_fpara_2023_1197956 crossref_primary_10_1371_journal_pntd_0000403 crossref_primary_10_1111_imm_12703 crossref_primary_10_1016_j_vaccine_2009_11_019 crossref_primary_10_1089_fpd_2013_1545 crossref_primary_10_3389_fimmu_2018_01763 crossref_primary_10_1016_j_vaccine_2013_11_034 crossref_primary_10_1016_S1471_4922_01_02117_1 crossref_primary_10_1586_erv_10_63 crossref_primary_10_1016_j_trstmh_2004_02_006 crossref_primary_10_1007_s00436_005_0081_z crossref_primary_10_1017_S0031182021000214 crossref_primary_10_1016_j_chom_2016_04_003 crossref_primary_10_1021_acs_jnatprod_6b00444 crossref_primary_10_1007_s00335_021_09887_z crossref_primary_10_1017_S0950268812001823 crossref_primary_10_1016_j_micinf_2005_07_025 crossref_primary_10_1016_j_chom_2012_10_001 crossref_primary_10_1046_j_1432_1033_2003_03658_x crossref_primary_10_1002_eji_200939699 crossref_primary_10_1016_j_vaccine_2014_01_001 crossref_primary_10_1164_rccm_200211_1320OC crossref_primary_10_1016_S1473_3099_14_70771_6 crossref_primary_10_1098_rspb_2013_2286 crossref_primary_10_4049_jimmunol_1203311 crossref_primary_10_1097_00001432_200212000_00008 crossref_primary_10_1016_j_imbio_2007_03_009 crossref_primary_10_1590_S0037_86822009000300021 crossref_primary_10_1016_j_jri_2019_08_001 crossref_primary_10_1086_522010 crossref_primary_10_1371_journal_pntd_0003341 crossref_primary_10_1371_journal_pntd_0001445 crossref_primary_10_4049_jimmunol_2300084 crossref_primary_10_4049_jimmunol_0900257 crossref_primary_10_1371_journal_pntd_0003170 crossref_primary_10_3390_pathogens11101163 crossref_primary_10_1371_journal_pmed_0030102 crossref_primary_10_1016_j_trstmh_2009_05_005 crossref_primary_10_1128_IAI_73_4_1995_2004_2005 crossref_primary_10_1038_s41598_020_68217_6 crossref_primary_10_1097_01_revmedmi_0000174307_33651_81 crossref_primary_10_1016_j_vaccine_2006_03_078 crossref_primary_10_1093_infdis_jir035 crossref_primary_10_1016_j_krcp_2016_07_002 crossref_primary_10_1016_j_vaccine_2012_11_012 crossref_primary_10_1111_j_1523_5378_2011_00916_x crossref_primary_10_1111_j_1365_3024_2010_01204_x crossref_primary_10_1038_mi_2017_20 crossref_primary_10_1016_j_vaccine_2018_04_066 crossref_primary_10_1073_pnas_0912327107 crossref_primary_10_1016_j_immuni_2014_04_010 crossref_primary_10_1111_pim_12194 crossref_primary_10_1371_journal_pntd_0011500 crossref_primary_10_3390_vaccines12070729 crossref_primary_10_1111_j_1365_3024_2005_00788_x crossref_primary_10_1016_j_pt_2020_09_002 crossref_primary_10_3103_S1068367421010122 crossref_primary_10_3389_fimmu_2020_577516 crossref_primary_10_1371_journal_pntd_0005180 crossref_primary_10_1016_j_clp_2010_08_005 crossref_primary_10_4049_jimmunol_1800101 crossref_primary_10_1155_2011_821578 crossref_primary_10_1371_journal_pntd_0000614 crossref_primary_10_3389_fimmu_2021_635985 crossref_primary_10_1016_j_vaccine_2016_07_040 crossref_primary_10_1128_IAI_74_3_1924_1932_2006 crossref_primary_10_1586_14760584_5_4_483 crossref_primary_10_2217_fmb_2017_0128 crossref_primary_10_1172_JCI97377 crossref_primary_10_1128_AEM_01983_06 crossref_primary_10_1017_S0950268807008886 crossref_primary_10_1016_j_exger_2020_110852 crossref_primary_10_1038_mi_2009_14 crossref_primary_10_1371_journal_pone_0266456 crossref_primary_10_1038_mi_2011_11 crossref_primary_10_1128_IAI_00827_08 crossref_primary_10_1111_j_1365_2249_2004_02719_x crossref_primary_10_3389_fimmu_2014_00434 crossref_primary_10_1046_j_1365_2249_2002_01908_x crossref_primary_10_22579_20112629_631 crossref_primary_10_1097_01_inf_0000132228_00778_e4 crossref_primary_10_1093_trstmh_trx010 crossref_primary_10_1179_136485906X118468 crossref_primary_10_1111_pim_12171 crossref_primary_10_1111_j_0141_9838_2004_00728_x crossref_primary_10_1111_j_1365_3024_2006_00904_x crossref_primary_10_1186_s12917_021_02752_w crossref_primary_10_1186_s40168_015_0103_8 crossref_primary_10_1097_ACI_0b013e32831f44a6 crossref_primary_10_1186_1471_2334_11_184 crossref_primary_10_1371_journal_pntd_0001890 crossref_primary_10_1590_S0037_86822007000200001 crossref_primary_10_1128_IAI_70_2_427_433_2002 crossref_primary_10_1371_journal_pntd_0000442 crossref_primary_10_1586_eri_12_23 crossref_primary_10_1186_1471_2334_6_88 crossref_primary_10_1586_eri_12_118 crossref_primary_10_1111_cei_12353 crossref_primary_10_1016_S0966_842X_01_02172_2 crossref_primary_10_1128_CMR_05040_11 crossref_primary_10_1111_j_1365_3156_2005_01541_x crossref_primary_10_1016_j_vetpar_2014_10_016 crossref_primary_10_1128_IAI_00687_06 crossref_primary_10_1016_j_ijpara_2006_02_011 crossref_primary_10_1017_S0031182008000322 crossref_primary_10_4049_jimmunol_1401638 crossref_primary_10_1016_j_vaccine_2009_05_075 crossref_primary_10_1097_COH_0b013e32835210cd crossref_primary_10_1016_j_vaccine_2012_10_026 crossref_primary_10_1371_journal_pntd_0001527 crossref_primary_10_1155_2014_913696 crossref_primary_10_1017_S095026881800119X crossref_primary_10_4049_jimmunol_1004136 crossref_primary_10_1084_jem_20200004 crossref_primary_10_1002_14651858_CD008603_pub2 crossref_primary_10_1371_journal_ppat_1007182 crossref_primary_10_3389_fimmu_2021_784141 crossref_primary_10_1016_j_parint_2009_02_001 crossref_primary_10_1038_mi_2013_50 crossref_primary_10_1128_CMR_00084_18 crossref_primary_10_1017_S0031182011000588 |
| Cites_doi | 10.1016/0264-410X(94)90012-4 10.1016/0264-410X(93)90005-I 10.1086/315830 10.1084/jem.178.4.1309 10.1086/515661 10.1086/314647 10.1002/eji.1830230914 10.1016/0035-9203(94)90069-8 10.1016/0264-410X(92)90204-W 10.1086/315051 10.1172/JCI115270 10.1093/infdis/170.4.962 10.1164/ajrccm.156.1.9606081 10.1093/oxfordjournals.aje.a121457 10.1017/S0031182000075557 10.4049/jimmunol.148.10.3264 10.1128/iai.61.2.729-733.1993 10.1093/infdis/171.3.659 10.1002/eji.1830211007 10.1093/infdis/173.1.269 10.1086/315837 10.1073/pnas.90.3.948 10.1111/j.1365-2249.1994.tb06548.x 10.1016/0264-410X(94)90033-7 10.1093/infdis/165.6.1042 10.1093/ajcn/25.11.1276 10.4049/jimmunol.148.11.3567 10.1201/9780429258589 10.1093/clinids/13.5.926 10.1016/S0167-5699(98)01397-8 10.1093/infdis/153.6.1126 10.4049/jimmunol.151.9.4857 10.1017/S0031182000081105 10.1016/0140-6736(92)92231-4 |
| ContentType | Journal Article |
| Copyright | 2002 INIST-CNRS Copyright © 2001, American Society for Microbiology 2001 |
| Copyright_xml | – notice: 2002 INIST-CNRS – notice: Copyright © 2001, American Society for Microbiology 2001 |
| DBID | AAYXX CITATION IQODW CGR CUY CVF ECM EIF NPM 7T5 H94 7X8 5PM |
| DOI | 10.1128/IAI.69.3.1574-1580.2001 |
| DatabaseName | CrossRef Pascal-Francis Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed Immunology Abstracts AIDS and Cancer Research Abstracts MEDLINE - Academic PubMed Central (Full Participant titles) |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) AIDS and Cancer Research Abstracts Immunology Abstracts MEDLINE - Academic |
| DatabaseTitleList | CrossRef MEDLINE - Academic AIDS and Cancer Research Abstracts MEDLINE |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine Biology |
| EISSN | 1098-5522 |
| EndPage | 1580 |
| ExternalDocumentID | PMC98058 11179329 14162131 10_1128_IAI_69_3_1574_1580_2001 iai_69_3_1574 |
| Genre | Clinical Trial Randomized Controlled Trial Research Support, Non-U.S. Gov't Journal Article |
| GrantInformation_xml | – fundername: Wellcome Trust |
| GroupedDBID | --- -DZ -~X .55 .GJ 0R~ 18M 29I 2WC 39C 3O- 4.4 41~ 53G 5GY 5RE 5VS 85S AAGFI AAYXX ABOCM ACGFO ADBBV ADXHL AENEX AGCDD AGVNZ AI. ALMA_UNASSIGNED_HOLDINGS AOIJS BAWUL BTFSW C1A CITATION CS3 D0S DIK DU5 E3Z EBS EJD F5P FRP GX1 H13 HYE HZ~ H~9 IH2 J5H KQ8 L7B MVM NEJ O9- OHT OK1 P2P RHI RNS RPM RSF SJN TR2 TWZ UPT VH1 W2D W8F WH7 WHG WOQ X7M Y6R ZGI ZXP ~KM IQODW CGR CUY CVF ECM EIF NPM PKN RHF UCJ VQA YIF 7T5 H94 7X8 5PM |
| ID | FETCH-LOGICAL-c478t-e40875f1924702d6dc4d6e8f4638ae31b81c97304a0e27d56844c7fbd7ecedbd3 |
| ISSN | 0019-9567 |
| IngestDate | Thu Aug 21 13:54:58 EDT 2025 Fri Jul 11 02:46:56 EDT 2025 Fri Jul 11 08:59:43 EDT 2025 Wed Feb 19 02:08:31 EST 2025 Mon Jul 21 09:14:58 EDT 2025 Tue Jul 01 01:57:36 EDT 2025 Thu Apr 24 22:51:33 EDT 2025 Wed May 18 15:27:50 EDT 2016 |
| IsDoiOpenAccess | false |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 3 |
| Keywords | Ascaris lumbricoides Vision disorder Suppression Vaccination Vibrio cholerae Helper cell Potential Subunit Association Interleukin 2 Bacteria Nematoda Human Cytokine Vaccine Parasitosis Helminthiasis Infection Ascariasis Toxin Eye disease Benzimidazole derivatives Nematode disease Blindness Bacteriosis Helmintha Vibrionaceae Nemathelminthia Cholera Invertebrata |
| Language | English |
| License | CC BY 4.0 |
| LinkModel | OpenURL |
| MergedId | FETCHMERGED-LOGICAL-c478t-e40875f1924702d6dc4d6e8f4638ae31b81c97304a0e27d56844c7fbd7ecedbd3 |
| Notes | ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Feature-1 content type line 23 ObjectType-Undefined-3 Corresponding author. Present address: Division of Infectious Diseases, St. George's Hospital Medical School, Cranmer Terrace, London SW17 0RE, United Kingdom. Phone: 44-20-8725-5827. Fax: 44-20-8725-3487. E-mail: pc102d@hotmail.com. |
| PMID | 11179329 |
| PQID | 17861102 |
| PQPubID | 23462 |
| PageCount | 7 |
| ParticipantIDs | pubmedcentral_primary_oai_pubmedcentral_nih_gov_98058 proquest_miscellaneous_17861102 crossref_primary_10_1128_IAI_69_3_1574_1580_2001 crossref_citationtrail_10_1128_IAI_69_3_1574_1580_2001 highwire_asm_iai_69_3_1574 proquest_miscellaneous_70629367 pascalfrancis_primary_14162131 pubmed_primary_11179329 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2001-03-01 |
| PublicationDateYYYYMMDD | 2001-03-01 |
| PublicationDate_xml | – month: 03 year: 2001 text: 2001-03-01 day: 01 |
| PublicationDecade | 2000 |
| PublicationPlace | Washington, DC |
| PublicationPlace_xml | – name: Washington, DC – name: United States |
| PublicationTitle | Infection and Immunity |
| PublicationTitleAlternate | Infect Immun |
| PublicationYear | 2001 |
| Publisher | American Society for Microbiology |
| Publisher_xml | – name: American Society for Microbiology |
| References | e_1_3_2_26_2 e_1_3_2_28_2 e_1_3_2_29_2 Mahanty S. (e_1_3_2_23_2) 1992; 148 e_1_3_2_21_2 e_1_3_2_22_2 e_1_3_2_24_2 e_1_3_2_25_2 Pearlman E. (e_1_3_2_27_2) 1993; 151 Hall A. (e_1_3_2_10_2) 1991; 22 e_1_3_2_9_2 e_1_3_2_38_2 e_1_3_2_8_2 e_1_3_2_16_2 e_1_3_2_37_2 e_1_3_2_7_2 e_1_3_2_17_2 e_1_3_2_6_2 e_1_3_2_18_2 e_1_3_2_39_2 e_1_3_2_19_2 e_1_3_2_30_2 Kullberg M. C. (e_1_3_2_15_2) 1992; 148 e_1_3_2_32_2 e_1_3_2_31_2 e_1_3_2_5_2 e_1_3_2_11_2 e_1_3_2_34_2 e_1_3_2_4_2 e_1_3_2_12_2 e_1_3_2_33_2 e_1_3_2_3_2 e_1_3_2_13_2 e_1_3_2_36_2 e_1_3_2_2_2 e_1_3_2_14_2 e_1_3_2_35_2 Linhares A. C. (e_1_3_2_20_2) 1996; 74 |
| References_xml | – ident: e_1_3_2_5_2 doi: 10.1016/0264-410X(94)90012-4 – ident: e_1_3_2_19_2 doi: 10.1016/0264-410X(93)90005-I – ident: e_1_3_2_9_2 doi: 10.1086/315830 – volume: 22 start-page: 84 year: 1991 ident: e_1_3_2_10_2 article-title: Albendazole and infections with Trichuris trichiura and Giardia intestinalis publication-title: S. E. Asian J. Trop. Med. Public Health – ident: e_1_3_2_39_2 doi: 10.1084/jem.178.4.1309 – ident: e_1_3_2_7_2 doi: 10.1086/515661 – ident: e_1_3_2_6_2 doi: 10.1086/314647 – ident: e_1_3_2_12_2 doi: 10.1002/eji.1830230914 – volume: 74 start-page: 491 year: 1996 ident: e_1_3_2_20_2 article-title: Immunogenicity, safety and efficacy of tetravalent rhesus-human, reassortant rotavirus vaccine in Belem, Brazil publication-title: Bull. W. H. O. – ident: e_1_3_2_4_2 doi: 10.1016/0035-9203(94)90069-8 – ident: e_1_3_2_17_2 doi: 10.1016/0264-410X(92)90204-W – ident: e_1_3_2_16_2 doi: 10.1086/315051 – ident: e_1_3_2_28_2 doi: 10.1172/JCI115270 – ident: e_1_3_2_31_2 doi: 10.1093/infdis/170.4.962 – ident: e_1_3_2_22_2 doi: 10.1164/ajrccm.156.1.9606081 – ident: e_1_3_2_13_2 doi: 10.1093/oxfordjournals.aje.a121457 – ident: e_1_3_2_11_2 doi: 10.1017/S0031182000075557 – volume: 148 start-page: 3264 year: 1992 ident: e_1_3_2_15_2 article-title: Infection with Schistosoma mansoni alters Th1/Th2 cytokine responses to a nonparasite antigen publication-title: J. Immunol. doi: 10.4049/jimmunol.148.10.3264 – ident: e_1_3_2_21_2 doi: 10.1128/iai.61.2.729-733.1993 – ident: e_1_3_2_24_2 doi: 10.1093/infdis/171.3.659 – ident: e_1_3_2_35_2 doi: 10.1002/eji.1830211007 – ident: e_1_3_2_37_2 – ident: e_1_3_2_29_2 doi: 10.1093/infdis/173.1.269 – ident: e_1_3_2_8_2 doi: 10.1086/315837 – ident: e_1_3_2_2_2 doi: 10.1073/pnas.90.3.948 – ident: e_1_3_2_30_2 doi: 10.1111/j.1365-2249.1994.tb06548.x – ident: e_1_3_2_38_2 doi: 10.1016/0264-410X(94)90033-7 – ident: e_1_3_2_32_2 doi: 10.1093/infdis/165.6.1042 – ident: e_1_3_2_25_2 – ident: e_1_3_2_34_2 doi: 10.1093/ajcn/25.11.1276 – volume: 148 start-page: 3567 year: 1992 ident: e_1_3_2_23_2 article-title: Parallel regulation of IL-4 and IL-5 in human helminth infections publication-title: J. Immunol. doi: 10.4049/jimmunol.148.11.3567 – ident: e_1_3_2_3_2 doi: 10.1201/9780429258589 – ident: e_1_3_2_26_2 doi: 10.1093/clinids/13.5.926 – ident: e_1_3_2_36_2 doi: 10.1016/S0167-5699(98)01397-8 – ident: e_1_3_2_14_2 doi: 10.1093/infdis/153.6.1126 – volume: 151 start-page: 4857 year: 1993 ident: e_1_3_2_27_2 article-title: Modulation of murine cytokine responses to mycobacterial antigens by helminth-induced T helper 2 cell responses publication-title: J. Immunol. doi: 10.4049/jimmunol.151.9.4857 – ident: e_1_3_2_18_2 doi: 10.1017/S0031182000081105 – ident: e_1_3_2_33_2 doi: 10.1016/0140-6736(92)92231-4 |
| SSID | ssj0014448 |
| Score | 2.1165826 |
| Snippet | Classifications
Services
IAI
Citing Articles
Google Scholar
PubMed
Related Content
Social Bookmarking
CiteULike
Delicious
Digg
Facebook
Google+
Mendeley
Reddit... To investigate the potential immunomodulatory effects of concurrent ascariasis on the cytokine response to a live oral vaccine, we measured cytokine responses... |
| SourceID | pubmedcentral proquest pubmed pascalfrancis crossref highwire |
| SourceType | Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 1574 |
| SubjectTerms | Adult Albendazole - therapeutic use Animals Anthelmintics - therapeutic use Antigens, Helminth - immunology Ascariasis - drug therapy Ascariasis - immunology Ascaris lumbricoides Ascaris lumbricoides - drug effects Ascaris lumbricoides - immunology Bacteriology Biological and medical sciences Cholera - prevention & control Cholera Toxin - immunology Cholera Vaccines - immunology Cholera Vaccines - therapeutic use Double-Blind Method Female Fundamental and applied biological sciences. Psychology Fungal and Parasitic Infections Humans Interferon-gamma - blood Interleukin-2 - blood Leukocytes, Mononuclear - immunology Male Microbiology Pathogenicity, virulence, toxins, bacteriocins, pyrogens, host-bacteria relations, miscellaneous strains toxin B Vaccination Vaccines, antisera, therapeutical immunoglobulins and monoclonal antibodies |
| Title | Human Infection with Ascaris lumbricoides Is Associated with Suppression of the Interleukin-2 Response to Recombinant Cholera Toxin B Subunit following Vaccination with the Live Oral Cholera Vaccine CVD 103-HgR |
| URI | http://iai.asm.org/content/69/3/1574.abstract https://www.ncbi.nlm.nih.gov/pubmed/11179329 https://www.proquest.com/docview/17861102 https://www.proquest.com/docview/70629367 https://pubmed.ncbi.nlm.nih.gov/PMC98058 |
| Volume | 69 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9QwELZKEYgLgpbHFig-cIuyJE7iJMeygLoVBQnaqrfIThwasU1W3Wx5_Ex-ETOx89jSqpRLtEqc2SSez-MZf54h5FUg4iyQUtgp2HfbF35uSya5HYM5dDOeeyLF0MD-R7576O8dB8drtzYHrKVlLcfpr0v3lfxPr8I56FfcJXuDnu2Ewgn4Df0LR-hhOP5TH-sI_NTwqfSGbPjgKRYWtGDUkTDIVUWmFtZ00XVEyzfHep6aBFu2RIEmPDhTy29FaTOM7CN9tqmtgV7qqWxYM9YES-qeCeug-lGUuFNhKZcwMFg5qFT1HUMPRyJNCx1mNIFeEP4BOUqfMB9AK0A3U9bk6K3lOp69-_XzcK7cv1ezwNFsZKm7FYBJVc21uumYkLU37qkK8NpmI1J90tmdLyCmOm8KHCDPZVb17sRiDs_RXJieG7i0kZABFawd3d3YBn9PG3ClB3TMlxoEbGXE18VhjGZ7g-HbDXTJIDMVcANdZepvM8Nw68R0Zzrm8dgb4202NsZ4g9tb1pZNcMHgdjTIxgFjUQKCEh4nXoKCEhSE1UHBp7_NwPlhbQzKrI35vm_mF_ptDWsRBL2-4olW51xtHmykAQtQyVmuS7hc5mNdpAoP5l4HD8h94zTRHY2Ah2RNlRvkji6j-nOD3N03BJFN8ruBBO1Uh6L6UQMJOoQEnS5oDwndbgAJWuUUtJauQIK2kKB1RQeQoEajaQMJ-oYaSNAOEnQACf1fKBwhQRESnQADCQqQoAYSj8jh-3cHk13blC2xUz-Malv5WCUix8hG6LCMZ6mfcRXlPpg6oTxXRm4ag2H1haNYmAU88v00zGUWqlRlMvMek_WyKtVTQp3Yk0EuMs5jAVPpME5D1-NRzh2pHCdjI8Lbjk1Sk9MfS8vMkmtUa0Sc7sa5Tmtz_S1breYkYnGaFKLom43I9oou9ULB4WOuB3e_bJUrAQOGq5KiVNVykbhhxMEHYVe3CB0OTgkPR-SJVsZeOia09Fg8IsGKmnYNMHn-6pWyOGmS6MeRE0RbN_8Mz8i9fux5Ttbrs6V6AX5JLbcbmP4BYIw3pg |
| linkProvider | National Library of Medicine |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Human+Infection+with+Ascaris+lumbricoides+Is+Associated+with+Suppression+of+the+Interleukin-2+Response+to+Recombinant+Cholera+Toxin+B+Subunit+following+Vaccination+with+the+Live+Oral+Cholera+Vaccine+CVD+103-HgR&rft.jtitle=Infection+and+immunity&rft.au=Cooper%2C+Philip+J.&rft.au=Chico%2C+Martha&rft.au=Sandoval%2C+Carlos&rft.au=Espinel%2C+Ivan&rft.date=2001-03-01&rft.issn=0019-9567&rft.eissn=1098-5522&rft.volume=69&rft.issue=3&rft.spage=1574&rft.epage=1580&rft_id=info:doi/10.1128%2FIAI.69.3.1574-1580.2001&rft.externalDBID=n%2Fa&rft.externalDocID=10_1128_IAI_69_3_1574_1580_2001 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0019-9567&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0019-9567&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0019-9567&client=summon |